Friday, 16 October 2026European Markets

AMG Stock Over 13% Down So Far On Thursday

Loading stream...

Amsterdam-based AMG (AEX-Index: AMG.AS) is currently experiencing significant market fluctuations. On Thursday, shares dropped an alarming 13.36% at 11:07 EST to reach EUR40.78. This noticeably poor performance happened amid otherwise buoyant trading sessions where the AEX-Index gained 1.58% and reached EUR787.73.

Previous Market Trend

Continuing its previous downward trend, AMG's closing price dropped 5.84% since last session to EUR47.07 - 5.884% below its 52-week high of EUR49.99.

About AMG Critical Materials N.V.

AMG Critical Materials N.V. is an international multi-national corporation engaged in the production and sale of engineered specialty metals and mineral products. It caters to a variety of markets, including but not limited to, transportation, infrastructure, energy production and supply, and specialty metals and chemicals. The company operates globally through three segments with primary operations in countries such as the US, China, Germany, and Brazil among others.

Financial Performance

AMG achieved an earnings per share (EPS) of EUR6.27 in its trailing twelve month earnings period, thus yielding considerable profits. However, recent market fluctuations have significantly reduced share value. The company's price-to-earnings ratio stands at 6.5, indicating that investors have low expectations or believe in a decelerating growth potential of AMG.

Return on Equity

AMG's return on equity, calculated by dividing net income by shareholders' equity, stands at an impressive 46.59% over the past twelve months. This is despite it stock price slump and indicates strong management practices as well as good returns for its investors.

More news about AMG (AMG.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com